Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Intensified TB treatment (DATURA) is a multi-drug therapeutic regimen being evaluated in the Phase III DATURA clinical trial (ANRS 12424). It is specifically designed for HIV-infected adults and adolescents hospitalized with tuberculosis and severe immunosuppression (CD4 count ≤ 100 cells/μL). The regimen consists of an initial 8-week phase using increased doses of rifampicin (35±5 mg/kg daily) and isoniazid (10±2 mg/kg daily), combined with standard doses of pyrazinamide and ethambutol. Additionally, the regimen includes adjunctive corticosteroid therapy with prednisone for 6 weeks and a 3-day course of albendazole. This intensified approach aims to improve survival rates in this high-risk population by providing more potent initial antimicrobial activity and managing the inflammatory response associated with severe TB-HIV co-infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Intensified TB treatment (DATURA).